Spermosens

Bolag

Spermosens

Spermosens är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar produkter för manlig infertilitet och individuellt anpassade fertilitetsbehandlingar. Forskning och utveckling bedrivs via egen teknologisk plattform som analyserar spermiekvalitén som vidare används för medicinskt underlag och potentiell befruktning. Störst verksamhet återfinns inom den nordiska marknaden.

Senaste publicering

I databasen

25 publicerade PM

Webbplats

Besök bolagets sida

Senaste nyheter och pressmeddelanden

12 visade
SPERM

Spermosens raises approx. SEK 4.85m in directed issue and calls EGM

The Board of Directors of Spermosens AB (publ) ("Spermosens" or the "Company") has today, pursuant to the authorisation granted by the Annual General Meeting held on 18 June 2026, resolved on a directed issue of approximately SEK 4.65 million through the issuance of up to 560,240,958 units, each consisting of one (1) share and one (1) warrant of series 2026/2029 issued free of charge (the "First Directed Issue"). The subscription price amounts to SEK 0.0083 per unit, corresponding to SEK 0.0083 per share, representing a discount of approximately fifteen (15) per cent compared with the volume-weighted average price (VWAP) of the Company's share during the ten (10) trading days immediately following the Company's call of capital under the Capital Facility.   The Board of Directors has furthermore resolved to convene an Extraordinary General Meeting to resolve on a separate directed issue of approximately SEK 0.2 million through the issuance of up to 24,096,384 units on the same terms and conditions, to Chairman of the Board Ulrik Spork and Duvold Holding ApS (the "Second Directed Issue" and, together with the First Directed Issue, the "Directed Issues"). Through the Directed Issues, the Company will receive gross proceeds of approximately SEK 4.85 million before transaction costs of approximately SEK 0.2 million. The Directed Issues are carried out pursuant to the Capital Facility announced by the Company on 7 May 2026 and approved by the Annual General Meeting held on 18 June 2026.

SPERM

Spermosens calls SEK 4.85 million under previously announced Capital Facility

Spermosens AB (publ) ("Spermosens" or the "Company") hereby announces that the Board of Directors has today resolved to call capital under the capital facility of SEK 4.85 million that was announced on 7 May 2026 and subsequently approved by the Annual General Meeting on 18 June 2026. In accordance with the terms of the Capital Facility, the full available amount of SEK 4.85 million has been called. The capital will be contributed to the Company through the issuance of units to the investors participating in the Capital Facility.